Key result
Cardiac myosin K104E mutation increases murine actin sliding velocities despite similar human in vitro properties.
Why the study?
Variable penetrance of the HCM-associated RLC K104E mutation in humans suggested subtle effects, prompting assessment of its mechanochemical impact on cardiac myosin.
The K104E mutation in the cardiac myosin regulatory light chain alters actin sliding velocities and incorporation into α-cardiac myosin, suggesting its impact depends on the myosin heavy chain backbone or disrupts RLC interactions with the lever arm domain.
K104E mouse data warrant no clinical action; leaves open human cardiomyopathy relevance and species-specific myosin effects.
Mutations in the cardiac myosin regulatory light chain (RLC, MYL2 gene) are known to cause inherited cardiomyopathies with variable phenotypes. In this study, we investigated the impact of a mutation in the RLC (K104E) that is associated with hypertrophic cardiomyopathy (HCM). Previously in a mouse model of K104E, older animals were found to develop cardiac hypertrophy, fibrosis, and diastolic dysfunction, suggesting a slow development of HCM. However, variable penetrance of the mutation in human populations suggests that the impact of K104E may be subtle. Therefore, we generated human cardiac myosin subfragment-1 (M2β-S1) and exchanged on either the wild type (WT) or K104E human ventricular RLC in order to assess the impact of the mutation on the mechanochemical properties of cardiac myosin. The maximum actin-activated ATPase activity and actin sliding velocities in the in vitro motility assay were similar in M2β-S1 WT and K104E, as were the detachment kinetic parameters, including the rate of ATP-induced dissociation and the ADP release rate constant. We also examined the mechanical performance of α-cardiac myosin extracted from transgenic (Tg) mice expressing human wild type RLC (Tg WT) or mutant RLC (Tg K104E). We found that α-cardiac myosin from Tg K104E animals demonstrated enhanced actin sliding velocities in the motility assay compared with its Tg WT counterpart. Furthermore, the degree of incorporation of the mutant RLC into α-cardiac myosin in the transgenic animals was significantly reduced compared with wild type. Therefore, we conclude that the impact of the K104E mutation depends on either the length or the isoform of the myosin heavy chain backbone and that the mutation may disrupt RLC interactions with the myosin lever arm domain.
No takes yet. Share an insight, caveat, or question.
Rasicci et al. (2021) studied Hypertrophic cardiomyopathy. K104E mutation in cardiac myosin regulatory light chain vs. Wild type (WT) regulatory light chain was evaluated on Mechanochemical properties including ATPase activity and actin sliding velocities. The K104E mutation in cardiac myosin regulatory light chain demonstrated enhanced actin sliding velocities in transgenic mice compared with wild type, though in vitro human properties were similar.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: